首页> 外文期刊>Neuropsychiatric Disease and Treatment >Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives
【24h】

Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives

机译:选择性血清素再摄取抑制剂诱发性功能障碍:当前的管理视角

获取原文
获取外文期刊封面目录资料

摘要

Any type of sexual dysfunction is an important problem in half of the patients with depressive disorder. On the other hand, one to a quarter of people without any depressive disorder experience sexual dysfunction. Antidepressant agents can lead to all types of sexual side effects including arousal, libido, orgasm and ejaculation problems. Selective serotonin reuptake inhibitors (SSRIs) are a widely used class of drugs which are prescribed for the treatment of a variety of disorders, including major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, generalized anxiety disorder, and impulse control disorders. It has been reported that one in eight people have utilized one of the SSRIs in the past 10 years. Some studies reported up to 80% of SSRI-induced sexual side effects. Management of SSRI-induced sexual dysfunction seems to be complex and hard. In this paper, SSRI-induced sexual dysfunction and new perspectives in the management of this problem were reviewed.
机译:任何类型的性功能障碍都是一半的抑郁症患者的重要问题。另一方面,一到四分之一的人没有任何抑郁症的人经历了性功能障碍。抗抑郁药可导致所有类型的性副作用,包括唤醒,性欲,性欲和射精问题。选择性血清素再摄取抑制剂(SSRIS)是一类广泛使用的药物,用于治疗各种疾病,包括主要的抑郁症,强迫症,错误紊乱,恐慌症,广义焦虑症和脉冲控制障碍。据报道,八分之一的人在过去的10年里使用了一个SSRIS。一些研究报告占SSRI诱导的性副作用的80%。 SSRI诱导的性功能障碍的管理似乎是复杂的并且很难。在本文中,综述了SSRI诱导的性功能障碍和管理此问题管理中的新观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号